Aimmune Therapeutics, Inc. (AIMT) Financial Statements (2025 and earlier)

Company Profile

Business Address 8000 MARINA BOULEVARD
BRISBANE, CA 94005-1884
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:371,600158,200200,500250,300296,300303,900
Cash and cash equivalents298,41879,88076,84472,56481,058107,511
Short-term investments59,93363,633118,626171,108202,113196,421
Other undisclosed cash, cash equivalents, and short-term investments13,24914,6875,0306,62813,129(32)
Receivables772     
Inventory, net of allowances, customer advances and progress billings4,076     
Inventory4,076     
Other undisclosed current assets(8,628)(9,123)1,736231(4,909)8,719
Total current assets:367,820149,077202,236250,531291,391312,619
Noncurrent Assets
Operating lease, right-of-use asset10,91311,51211,904  
Property, plant and equipment27,50628,60428,71329,41426,82426,328
Long-term investments and receivables13,25614,6615,0386,58413,177 
Long-term investments13,25614,6615,0386,58413,177 
Other undisclosed noncurrent assets55751550712,24712,761608
Total noncurrent assets:52,23255,29246,16248,24552,76226,936
TOTAL ASSETS:420,052204,369248,398298,776344,153339,555
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities43,08045,16841,42141,16936,10537,977
Accounts payable13,95213,88211,94114,08610,5178,833
Accrued liabilities29,12831,28629,48027,08325,58829,144
Debt2,3152,2572,163   
Other liabilities242321201935
Other undisclosed current liabilities   2,0221,967 
Total current liabilities:45,41947,44843,60543,21138,09138,012
Noncurrent Liabilities
Long-term debt and lease obligation138,07451,55250,93538,52637,268 
Long-term debt, excluding current maturities128,25041,02839,78238,52637,268 
Liabilities, other than long-term debt1,5121,3451,1661,0298602,596
Other liabilities1,5121,3451,1661,0298602,596
Operating lease, liability9,82410,52411,153  
Other undisclosed noncurrent liabilities    11,03611,633 
Total noncurrent liabilities:139,58652,89752,10150,59149,7612,596
Total liabilities:185,005100,34595,70693,80287,85240,608
Equity
Equity, attributable to parent235,047104,024152,692204,974256,301298,947
Common stock766666
Additional paid in capital1,045,989828,618810,328798,058786,681775,283
Accumulated other comprehensive income (loss)1638014023663(108)
Accumulated deficit(811,112)(724,680)(657,782)(593,326)(530,449)(476,234)
Total equity:235,047104,024152,692204,974256,301298,947
TOTAL LIABILITIES AND EQUITY:420,052204,369248,398298,776344,153339,555

Income Statement (P&L) ($ in thousands)

6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
Revenues 575     
Cost of revenue(257)     
Gross profit:318     
Operating expenses(85,601)(66,986)(64,602)(63,188)(55,028)(58,433)
Operating loss:(85,283)(66,986)(64,602)(63,188)(55,028)(58,433)
Nonoperating income1,1996,939    
Investment income, nonoperating978     
Other nonoperating income (expense)221     
Interest and debt expense(2,229)(4,904)(4)   
Loss from continuing operations before equity method investments, income taxes:(86,313)(64,951)(64,606)(63,188)(55,028)(58,433)
Other undisclosed income (loss) from continuing operations before income taxes  (1,204)473587911,417
Loss from continuing operations before income taxes:(86,313)(66,155)(64,559)(62,830)(54,237)(57,016)
Income tax expense (benefit)(119)(743)104(48)(29)18
Loss from continuing operations:(86,432)(66,898)(64,455)(62,878)(54,266)(56,998)
Loss before gain (loss) on sale of properties:(86,432)(66,898)(64,455)(62,878)(54,266)(56,998)
Net loss available to common stockholders, diluted:(86,432)(66,898)(64,455)(62,878)(54,266)(56,998)

Comprehensive Income ($ in thousands)

6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
Net loss:(86,432)(66,898)(64,455)(62,878)(54,266)(56,998)
Other comprehensive loss(10)     
Comprehensive loss:(86,442)(66,898)(64,455)(62,878)(54,266)(56,998)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent93(60)(97)17417130
Comprehensive loss, net of tax, attributable to parent:(86,349)(66,958)(64,552)(62,704)(54,095)(56,968)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: